Monica M. Marcus
About
Monica M. Marcus is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Psychiatry and Mental health.
According to data from OpenAlex, Monica M. Marcus has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Cellular and Molecular Neuroscience, 21 papers in Molecular Biology and 18 papers in Psychiatry and Mental health. Recurrent topics in Monica M. Marcus's work include Neurotransmitter Receptor Influence on Behavior (28 papers), Neuroscience and Neuropharmacology Research (24 papers) and Schizophrenia research and treatment (16 papers). Monica M. Marcus is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (28 papers), Neuroscience and Neuropharmacology Research (24 papers) and Schizophrenia research and treatment (16 papers). Monica M. Marcus collaborates with scholars based in Sweden, Denmark and United States. Monica M. Marcus's co-authors include Torgny H. Svensson, Kent Jardemark, George G. Nomikos, T.H. Svensson, Jan M. Mathé, Åsa Konradsson‐Geuken, Jonas Andersson, P. Hertel, Björn Schilström and G.G. Nomikos and has published in prestigious journals such as Biological Psychiatry, Neuropsychopharmacology and Psychopharmacology.
In The Last Decade
Monica M. Marcus
44 papers receiving 1.1k citations
Peers
Monica M. Marcus
Agnès L. Auclair France
Kouji Fukuyama Japan
Teresa Tallerico Canada
Laetitia Cistarelli France
Qing‐Shan Yan United States
Jorge Pérez Italy
Karla Drescher Germany
W. Schmid‐Burgk Switzerland
Robert B. Innis United States
Citations per year, relative to Monica M. Marcus Monica M. Marcus (= 1×)
peers
Agnès L. Auclair
Countries citing papers authored by Monica M. Marcus
Since
Specialization
Citations
This map shows the geographic impact of Monica M. Marcus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monica M. Marcus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monica M. Marcus more than expected).
Fields of papers citing papers by Monica M. Marcus
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Monica M. Marcus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monica M. Marcus. The network helps show where Monica M. Marcus may publish in the future.
Co-authorship network of co-authors of Monica M. Marcus
This figure shows the co-authorship network connecting the top 25 collaborators of Monica M. Marcus. A scholar is included among the top collaborators of Monica M. Marcus based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monica M. Marcus. Monica M. Marcus is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yamazaki, Mayako, Noriyuki Yamamoto, Junko Yarimizu, et al.. (2018). Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of cognitive dysfunction in schizophrenia. European Neuropsychopharmacology. 28(5). 620–629.
2.
Björkholm, Carl, Monica M. Marcus, Åsa Konradsson‐Geuken, Kent Jardemark, & Torgny H. Svensson. (2017). The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. European Neuropsychopharmacology. 27(4). 411–417.
3.
Björkholm, Carl, Monica M. Marcus, Åsa Konradsson‐Geuken, et al.. (2014). Adjunctive Treatment with Asenapine Augments the Escitalopram-Induced Effects on Monoaminergic Outflow and Glutamatergic Neurotransmission in the Medial Prefrontal Cortex of the Rat. The International Journal of Neuropsychopharmacology. 18(3). pyu068–pyu068.
4.
Marcus, Monica M., et al.. (2012). Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 39(1). 143–148.
5.
Jardemark, Kent, et al.. (2011). Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology. 221(1). 115–131.
6.
Marcus, Monica M., et al.. (2010). Reboxetine Enhances the Olanzapine-Induced Antipsychotic-Like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission. Neuropsychopharmacology. 35(9). 1952–1961.
7.
Jardemark, Kent, Monica M. Marcus, Mohammed Shahid, & Torgny H. Svensson. (2010). Effects of asenapine on prefrontalN‐methyl‐D ‐aspartate receptor‐mediated transmission: Involvement of dopamine D1 receptors. Synapse. 64(11). 870–874.
8.
Schilström, Björn, Åsa Konradsson‐Geuken, Jens Gertow, et al.. (2010). Effects of S‐citalopram, citalopram, and R‐citalopram on the firing patterns of dopamine neurons in the ventral tegmental area,N‐methyl‐D ‐aspartate receptor‐mediated transmission in the medial prefrontal cortex and cognitive function in the rat. Synapse. 65(5). 357–367.
9.
Marcus, Monica M., et al.. (2009). Adjunctive α2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission. The International Journal of Neuropsychopharmacology. 13(7). 891–903.
10.
Jardemark, Kent, Åsa Konradsson‐Geuken, Björn Schilström, Monica M. Marcus, & Torgny H. Svensson. (2009). Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine. Synapse. 63(10). 913–920.
11.
Marcus, Monica M., et al.. (2009). Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology. 204(2). 251–264.
12.
Hertel, P., Michael Didriksen, Bruno Pouzet, et al.. (2007). Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: Characterisation of its in vitro profile and pre-clinical antipsychotic potential. European Journal of Pharmacology. 573(1-3). 148–160.
13.
Marcus, Monica M., Åsa Konradsson‐Geuken, Kent Jardemark, et al.. (2007). Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology. 196(3). 417–429.
14.
Jardemark, Kent, Monica M. Marcus, Åsa Konradsson‐Geuken, & Torgny H. Svensson. (2005). The combination of nicotine with the D2 antagonist raclopride or the weak D4 antagonist L-745,870 generates a clozapine-like facilitation of NMDA receptor-mediated neurotransmission in pyramidal cells of the rat medial prefrontal cortex. The International Journal of Neuropsychopharmacology. 8(2). 157–162.
15.
Marcus, Monica M., et al.. (2005). Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. The International Journal of Neuropsychopharmacology. 8(3). 315–327.
16.
Marcus, Monica M.. (2002). Biochemical effects in brain of low doses of haloperidol are qualitatively similar to those of high doses. European Neuropsychopharmacology. 12(5). 379–386.
17.
Marcus, Monica M., Jan M. Mathé, George G. Nomikos, & T.H. Svensson. (2001). Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens. Neuropharmacology. 40(4). 482–490.
18.
Svensson, T.H., et al.. (1997). Interactions between Catecholamines and Serotonin: Relevance to the Pharmacology of Schizophrenia. Advances in pharmacology. 42. 814–818.
19.
Svensson, Torgny H., et al.. (1995). Mode of Action of Atypical Neuroleptics in Relation to the Phencyclidine Model of Schizophrenia: Role of 5-HT2 Receptor and α1-Adrenoreceptor Antagonism. Journal of Clinical Psychopharmacology. 15(1 Suppl 1). 11S–18S.
20.
Marcus, Monica M., et al.. (1994). Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedeberg s Archives of Pharmacology. 349(3). 236–43.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Agnès L. Auclair Breakdown of academic impact, for papers by Kouji Fukuyama Breakdown of academic impact, for papers by Elisabetta Filomena Buonaguro Breakdown of academic impact, for papers by Teresa Tallerico Breakdown of academic impact, for papers by Laetitia Cistarelli Breakdown of academic impact, for papers by Qing‐Shan Yan Breakdown of academic impact, for papers by Jorge Pérez Breakdown of academic impact, for papers by Karla Drescher Breakdown of academic impact, for papers by W. Schmid‐Burgk Breakdown of academic impact, for papers by Robert B. Innis